Cellectis (LSE:0WA2) - Stock Price, News & Analysis

0WA2 Stock Overview

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. More details

0WA2 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 29.22% per year

Trading at good value compared to peers and industry

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Cellectis S.A. Competitors

Bioventix

AIM:BVXP

UK£195.7m

Oxford Biomedica

LSE:OXB

UK£442.5m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Avacta Group

AIM:AVCT

UK£179.3m

Price History & Performance

Summary of all time highs, changes and price drops for Cellectis
Historical stock prices
Current Share Price	€1.71
52 Week High	€3.43
52 Week Low	€1.64
Beta	3.2
11 Month Change	-2.06%
3 Month Change	-18.67%
1 Year Change	-34.23%
33 Year Change	-77.37%
5 Year Change	-86.49%
Change since IPO	-93.24%

Recent updates

Shareholder Returns

	0WA2	GB Biotechs	GB Market
7D	-0.4%	2.0%	1.7%
1Y	-34.2%	-17.5%	8.3%

Return vs Industry: 0WA2 underperformed the UK Biotechs industry which returned -17.5% over the past year.

Return vs Market: 0WA2 underperformed the UK Market which returned 8.3% over the past year.

Price Volatility

Is 0WA2's price volatile compared to industry and market?
0WA2 volatility
0WA2 Average Weekly Movement	3.8%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0WA2 has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0WA2's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	219	Andre Choulika	www.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Cellectis S.A. Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
0WA2 fundamental statistics
Market cap	€172.76m
Earnings (TTM)	-€81.12m
Revenue (TTM)	€34.61m

5.0x

P/S Ratio

-2.1x

P/E Ratio

Is 0WA2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0WA2 income statement (TTM)
Revenue	US$36.04m
Cost of Revenue	US$737.00k
Gross Profit	US$35.31m
Other Expenses	US$119.78m
Earnings	-US$84.48m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.84
Gross Margin	97.96%
Net Profit Margin	-234.39%
Debt/Equity Ratio	34.5%

How did 0WA2 perform over the long term?

See historical performance and comparison

0WA2 Stock Overview

Rewards

Risk Analysis

Cellectis S.A. Competitors

AIM:BVXP

UK£195.7m

LSE:OXB

UK£442.5m

AIM:TRX

UK£40.6m

AIM:AVCT

UK£179.3m

Price History & Performance

Recent News & Updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 3Q 2023)

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.089 loss in 2Q 2023)

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Recent updates

Cellectis Presents Multiple Strategies to Enhance Car T-Cell Efficacy in Solid Tumors at the SITC Annual Meeting

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 3Q 2023)

Cellectis S.A. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.089 loss in 2Q 2023)

Cibus, Inc. Achieves Positive Initial Field Trial Results for Stacked Gene Editing Herbicide Tolerant Traits in Rice

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

New minor risk - Share price stability

Cellectis Announces Chief Financial Officer Changes

No longer forecast to breakeven

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.089 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Now 21% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT